Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

This systematic review details monitoring and safety guidelines for primary care physicians regarding Janus kinase and tyrosine kinase 2 inhibitors used in treating inflammatory skin conditions, emphasizing their efficacy and the importance of updated knowledge due to associated box warnings and increasing use.

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

This study found that the JAK1 rs310241 AG genotype is associated with a 4.6-fold increased risk of alopecia areata, whereas JAK2 polymorphisms showed no significant link, suggesting a potential genetic susceptibility factor warranting further research.

This study found that ruxolitinib modulated inflammatory changes and stimulated growth factor signals by blocking the JAK-STAT pathway in an in vitro model of alopecia areata.